Brain NAD in Alzheimer's Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Alzheimer Disease (AD). Basic parameters: 65 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Measurement of Brain NAD Levels in Alzheimer's Patients and Control Subjects by 1H-MRS
Overview
The goal of this observational study is to learn about the levels of nicotinamide adenine dinucleotide (NAD) in the brains of people with Alzheimer's disease. The study aims to determine if brain NAD levels are lower in people with Alzheimer's disease compared with people of the same age group who do not have Alzheimer's disease. Participants with or without Alzheimer's disease will have a brain imaging session where NAD will be measured using magnetic resonance spectroscopy (MRS). Eight months later, they will have a second, similar, brain imaging session.
Primary outcome measures
- Brain NAD [Time frame: At enrollment and 8 months after enrollment]
Eligibility criteria
Inclusion criteria
- Participants are able to come to the Florida Atlantic University Clinical Research Unit, are verbal and ambulatory.
- Age 65 to 80 included.
- People with Alzheimer's disease (AD): AD diagnosis established by the person's physician according to the following criteria: clinical diagnosis AND either positive amyloid PET-scan or FDA-approved positive CSF or blood test.
Exclusion criteria
- Under the age of 65 or over the age of 80.
- Advanced dementia such that the person would require sedation for undergoing an MRI scan.
- Receiving anti-amyloid intravenous treatments Leqembi or Kinsula.
- Having an MRI-incompatible pacemaker or other MRI-incompatible hardware (e.g. comprising a metallic part).
- Having a history of seizures.
- Working at night.
- Having cancer or having been diagnosed with cancer within the last 5 years (excluding superficial squameous or basal cell cancer).
- People with no AD: MoCA test result lower than 26.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-control
Study locations
United States · 1 center
- FAU Clinical Research Unit — Boca Raton
Identifiers
NCT: NCT07127510 · IRB2504137